Author

Junhui Li

University of Massachusetts Chan Medical SchoolORCID 0000-0003-3973-1700Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Lihua Julie ZhuiD· 2 shared Arthur M. MercurioiD· 1 shared Emma MohlmanniD· 1 shared Hadiya K. GiwaiD· 1 shared Hira Lal Goel· 1 shared Jason Robert PitarresiiD· 1 shared Jennifer S. Morgan· 1 shared Jessica PeuraiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Lihua Julie ZhuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Biological ChemistryPeer-reviewedAug 10, 2026

Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer

Michael W. Lero, Jennifer S. Morgan, Michael-Anthony Card…·Leslie M. J. Shaw

This study identifies IRS2 as a mediator of resistance to PI3K pathway inhibitors in PIK3CA mutant breast cancer by sustaining PI3K signaling through FOXO3-mediated regulation.

DOI 10.1016/j.jbc.2026.113426

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedSep 3, 2025

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer

Katherine C. Murphy, Kelly D. DeMarco, Lin Zhou…·Marcus A. Ruscetti

This study shows that MYC and p53 alterations in prostate cancer cooperate via VEGF signaling to suppress T cell activity and immunotherapy responses, and that targeting VEGFR2 can enhance immunotherapy efficacy.

10 citationstop 5%

mousehuman

𝕏 PostBluesky